Chronic Kidney Disease (Chronic Renal Failure) – Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Chronic
Kidney Disease (Chronic Renal Failure) – Global API Manufacturers,
Marketed and Phase III Drugs Landscape, 2018”
drug pipelines
has been added to ResearchAndMarkets.com’s offering.

Chronic Kidney Disease (Chronic Renal Failure) – Global API
Manufacturers, Marketed and Phase III Drugs Landscape, 2018′ report
provides comprehensive insights about marketed and Phase III products
for Chronic Kidney Disease (Chronic Renal Failure) . The report includes
information of marketed products including their product description,
patent details, forecasted sales till 2020 & API manufacturer details by
country.

Coverage of API manufacturers for Chronic Kidney Disease (Chronic Renal
Failure) marketed products spanning across United States, Europe, China
and India. The manufacturers’ details include manufacturers’ name along
with their location.

This report provides a comprehensive understanding of the emerging Phase
III therapies for Chronic Kidney Disease (Chronic Renal Failure) which
can turn out to be future prospective competitors for the marketed
products. It will also put light on the current market trends. Their
forecasted global sales are also provided till 2020.

Key Topics Covered:

1. Report Introduction

2. Chronic Kidney Disease (Chronic Renal Failure): Overview

  • Risk Factors
  • Causes
  • Symptoms
  • Pathophysiology
  • Prognosis
  • Diagnosis
  • Treatment

3. Comparative Analysis of Marketed and Emerging Products

4. Marketed Therapies

4.1. Company name

  • Product Description
  • Route of Synthesis
  • Mechanism of Action
  • Pharmacology
  • Pharmacodynamics
  • Pharmacokinetics
  • Adverse Reactions
  • Clinical Trials
  • Regulatory Milestones
  • Product Development Activities

4.1.1 Product Details

  • United States
  • Europe

4.1.2 Global Sales Assessment

  • Historical Global Sales
  • Forecasted Global Sales

4.1.3 Patent Details

Other marketed products in the detailed report

5. Emerging Therapies (Phase III)

5.1 Company Name

  • Product Description
  • Research and Development
  • Product Development Activities

5.1.1 Forecasted Global Sales

Other Phase III profiles in the detailed report

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/6n3nfs/chronic_kidney?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Liver
and Kidney Disorders Drugs